A prospective study on the use of rivastigmine transdermal patch in alzheimer's dementia in a routine clinical setting;Estudo prospectivo do uso de adesivo transdérmico de rivastigmina em doença de alzheimer em ambiente clinico

Dementia e Neuropsychologia

Volumn 4, Issue 3, 2010, Pages 245-249

  Nazir, Ejaz ^a   Mushtaq, Muhammad ^a  

^a Shelton Hospital   (United Kingdom)

Author keywords

Alzheimer's dementia; Clinical settings; Longitudinal study; Observational study; Rivastigmine; Transdermal patch

Indexed keywords

EID: 77958131316     PISSN: 19805764     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1980-57642010DN40300014     Document Type: Article

References (12)

1. Mercier F, Lefèvre G, Huang HL, Schmidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided by a trans-dermal patch versus capsules; Curr Med Res Opin 2007;23: 3199-31204.
2. Cummings J, Wimblad B. A Rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia Expert Rev Neurother 2007;7:1457-1463.
3. Winblad B, Cummings J, Andreasen N, et al. A six month double-blind, randomised, placebo-controlled study of a transdermal patch in Alzheimer's disease: rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-467.
4. th edition; World Health Organisation; Geneva.
5. NICE Guidance - Technology Appraisal 111- Alzheimer disease (National Institute of Clinical Excellence- UK).
6. Lefevre G, Sedek G, Huang H-LA, et al. Pharmacokinetics of a Rivastigmine patch formulation in healthy volunteers, relative effects of body site application; J Clin Pharmacol 2007; 47:471-478.
7. Lefevre G, Pommier F, Sedek G, et al. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects; J Clin Pharmacol 2008;48:246-252.
8. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for Rivastigmine patch relative to capsules for the treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:485-491.
9. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract 2009;63:799-805.
10. Sadowsky CH, Dengiz A, Olin JT, Koumaras B, Meng X, Brannan S; US38 study group. Switching from donepezil tablets to rivastigmine trans-dermal patch on Alzheimer's disease. Am J Alzhemers Dis Other Demen 2009;24:267-275.
11. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-1327.
12. Lefèvre G, Sedek G, Jhee S, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008;83:106-114.